



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Ralph A. REISFELD, et al.

Serial No. 10/090,183

Filed: March 2, 2002

For: DNA VACCINE AGAINST
PROLIFERATING ENDOTHELIAL CELLS
AND METHODS OF USE THEREOF

Examiner: Not Yet Assigned

Attorney Docket No.: (TSRI-829.0)

Group Art: 1645

RECEIVED

APR 30 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D. C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56, §1.97 and §1.98, documents that may be material to the examination of this application are listed on the attached PTO-1449 form. Copies of each document are enclosed.

The cited documents disclose numerous specific features. There has been no attempt to enumerate each and every feature disclosed by each document, however. The Examiner is requested to review these documents and to determine the extent of the materiality of the document disclosures, if any, with respect to the present invention.

The discussion of any art and the citation of any document herein is not to be construed as an admission that the art or document disclosure is necessarily within the invention field of endeavor, that the art or document disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that the art or document disclosure is otherwise necessarily prior art as defined by the patent law with respect to the instant invention and application.


Serial No. 10/090,183
Filed: March 2, 2002

-2-

Also, there is reserved the right to later set forth how the claimed invention is distinguished over the disclosure of any document or other art, including the disclosures of the art and documents recited herein, and that may be cited by the Examiner in rejecting a claim in the instant patent application.

The recitation herein of the art and documents is not to be construed as an assertion that more pertinent art could not possibly be in existence.

Respectfully submitted,

By 
Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180


Serial No. 10/090,183
Filed: March 2, 2002

-3-

CERTIFICATE OF MAILING

I hereby certify that this correspondence and attachments are being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on 23 April 2003


Talivaldis Cepuritis



Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	10/090,183
Filing Date	March 2, 2002
First Named Inventor	Ralph A. REISFELD
Art Unit	1645
Examiner Name	
Attorney Docket Number	TSRI-829.0

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

control number.

RECEIVED

[illegible]


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Footnote
		Country Code ² Number* Kind Code ³ (if known)	MM-DD-YYYY			
		WO 02/03961 A1	1/17/2002	Corixa Corp.		

Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

APR 28 2003



PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Application Number

10/090,183

Filing Date

March 2, 2002

First Named Inventor

Ralph A. REISFELD

Art Unit

1645

Examiner Name

Attorney Docket Number

TSRI-829.0

Complete if Known

RECEIVED
APR 30 2003
TECH CENTER 1600/2900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Shin SASAKI, et al., NATURE BIOTECHNOLOGY, Vol. 19, pp. 543-547 (June 2001).	
		Nicholas P. RESTIFO, NATURE BIOTECHNOLOGY, Vol. 19, pp. 527-528 (June 2001).	
		Wolgange W. LEITNER, et al., CANCER RESEARCH, Vol. 60, pp. 51-55 (January 1, 2000).	
		N P. RESTIFO et al. GENE THERAPY Vol 7 pp 89-92 (2000)	
		Bruce A. KEYT, et al., THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 10, pp. 5638-5646 (1996).	
		Yu-Quan WEI, et al., NATURE MEDICINE, Vol. 6, No. 10, pp. 1160-1166 (October 2000)	
		William MATTHEWS, et al., PROC. NAT'L ACAD. SCI., USA, Vol. 88, pp 9026-9030 (October 1991)	
		Timothy P. QUINN, et al., PROC. NAT'L ACAD. SCI., USA, Vol. 90, pp. 7533-7537 (Aug. 1993).	
		Rong XIANG, et al., CLINICAL CANCER RESEARCH, Vol. 7, pp. 856s-864s (March 2001) (Suppl.).	
		Andreas G. NIETHAMMER et al. NATURE MEDICINE Vol 8 (12), pp 1369-1375 (December, 2002).	

**Examiner
Signature**

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2